Evidence map›Paper›PMID 41789089›Full record

ArticleFrontiers in immunology2026

ScRNA-seq reveals dynamic macrophage heterogeneity in chronic liver disease progression and prognostic biomarkers

Qi Pan, Xinru Wang, Borui Li, Zhenzhen Cai, Shuwen Chen, Jiahong Hu, Xuenan Yuan, Jie Yang, An-Yuan Guo, Zhihong Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. A Mouse in vivo Model Mimicking MASH-Related HCC Pathogenesis.Journal of hepatocellular carcinoma · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qi Pan *School of Life and Health Sciences, Institute of Biomedical Research, Hainan Province Key Laboratory of One Health, Collaborative Innovation Center of Life and Health, Hainan University, Haikou, Hainan, China.
Xinru Wang *MOE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, Hubei, China.
Borui LiMOE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zhenzhen CaiMOE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, Hubei, China.
Shuwen ChenMOE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, Hubei, China.
Jiahong HuSchool of Life and Health Sciences, Institute of Biomedical Research, Hainan Province Key Laboratory of One Health, Collaborative Innovation Center of Life and Health, Hainan University, Haikou, Hainan, China.
Xuenan YuanMOE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, Hubei, China.
Jie YangMOE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, Hubei, China.
An-Yuan GuoDepartment of Thoracic Surgery, West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China.
Zhihong ZhangSchool of Life and Health Sciences, Institute of Biomedical Research, Hainan Province Key Laboratory of One Health, Collaborative Innovation Center of Life and Health, Hainan University, Haikou, Hainan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metabolic dysfunction-associated steatohepatitis (MASH)-induced chronic liver diseases (CLDs) were worldwide prevalence and incidence. The stage-resolved cellular and molecular programs remained incompletely defined. This study aimed to resolve stage-specific immune and transcriptional features across CLDs processes and to identify prognostic biomarkers. Methods: We integrated single-cell RNA sequencing datasets from healthy liver, MASH, cirrhosis and HCC to construct a stage-resolved cellular atlas. We performed cell-state scoring, diffusion pseudotime, gene regulatory network inference, and cell-cell interaction to decipher various macrophages and T cells transcriptional profiles. We established a method of gene sets enrichment score to detect prognostic markers and employed RNA fluorescence Results: The integrated atlas revealed the heterogeneity cell-subtype composition and transcriptional features across CLD stages. In MASH, CXCL3 Conclusion: We provided a stage-resolved framework to delineated macrophage heterogeneity during CLDs progression and identified SPP1 and KLF2 as candidate prognostic biomarkers and potential therapeutic targets in HCC.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularKruppel-Like Transcription FactorsLiver NeoplasmsMacrophagesOsteopontinChronic DiseaseDisease ProgressionHumansPrognosisRNA-SeqSingle-Cell AnalysisSingle-Cell Gene Expression AnalysisBiomarkers, TumorKLF2 protein, humanKruppel-Like Transcription FactorsOsteopontinSPP1 protein, humancell heterogeneitychronic liver diseases processesmacrophage-T cell interactionsprognostic biomarkersscRNA-seq

Identifiers

PMID41789089
PMCPMC12957215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.